Cuban public registry of clinical trials detailed on its official website that the study is also aimed at assessing the anti-inflammatory and clinical response in Covid-19-treated patients.
It will be an exploratory, controlled, open and monocentric research; and there will be two groups: experimental and control.
The latter (control group) will be administered as treatment the one intended for seriously ill Covid-19 patients at the National Care Protocol for Covid-19, except for Itoluzimab, a monoclonal antibody with anti-inflammatory and immunoregulatory effect.
The experimental one will receive intravenous anti-SARS-Cov-2 gamma globulin, 150 mg one-single dose.
According to selection criteria, in addition to the condition as a serious Covid-19 patient, those of both sexes aging 19 from 75 years old, with less than 10 days of evolution of the disease from the onset of symptoms, will be included too.
Those ventilated and who suffer from acute and chronic kidney disease or even have a previous history of adverse reaction to intravenous gamma globulin, as well as those who are pregnant or breastfeeding, among other requirements, will be excluded as well.
Cuban protocol for treating Covid-19 patients is currently passing through version 1.6; and since the onset of the disease in the country, the main goal is able-bodied people do not come down with coronavirus, and if someone falls sick, it is critical not let them to get seriously ill.
pgh/Pll/msm / alb/gdc